# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Trevena (NASDAQ:TRVN) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.40) by 42...
Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines fo...